Mildred D. Gottwald

机构：Fitbit (United States)

发表论文 38 篇 · 总被引 2517 次 · h-index 17

代表论文

• Randomized, Controlled Trial of the FGF21 Analogue Pegozafermin in NASH (2023 · New England Journal of Medicine · 被引 476)
• Efficacy and Safety of Aldafermin, an Engineered FGF19 Analog, in a Randomized, Double-Blind, Placebo-Controlled Trial of Patients With Nonalcoholic Steatohepatitis (2020 · Gastroenterology · 被引 267)
• Efficacy and safety study of cenicriviroc for the treatment of non-alcoholic steatohepatitis in adult subjects with liver fibrosis: CENTAUR Phase 2b study design (2016 · Contemporary Clinical Trials · 被引 198)
• Therapies for dopaminergic‐induced dyskinesias in parkinson disease (2011 · Annals of Neurology · 被引 100)
• Pharmacokinetics, Safety, and CCR2/CCR5 Antagonist Activity of Cenicriviroc in Participants With Mild or Moderate Hepatic Impairment (2016 · Clinical and Translational Science · 被引 53)
• MASH Resolution Index: development and validation of a non-invasive score to detect histological resolution of MASH (2024 · Gut · 被引 37)